Huma, a UK-based healthcare technology company, recently announced that it has raised more than $80 million in its latest funding round, a Series D, escalating its total funding to over $300 million. Notable new and returning investors participated in the round, including pharmaceutical giant AstraZeneca, Leaps by Bayer, Hat Technology Fund 4 by HAT SGR, and HV Fund by Hitachi Ventures.
Alongside the funding announcement, Huma introduced its latest innovation, the Huma Cloud Platform. This new product offers a no-code environment that facilitates the creation of disease management applications. It features a robust library of pre-built modules, extensive device connectivity options, and comprehensive APIs for seamless integrations. This cloud-agnostic platform also supports hosting and the deployment of predictive and diagnostic AI algorithms.
Dr. Juergen Eckhardt from Leaps by Bayer expressed strong endorsement for Huma, citing the company’s considerable progress and their effective growth strategies that leverage next-generation AI capabilities. He emphasized Huma’s potential to significantly enhance digital health solutions in partnership with pharmaceutical companies, focusing on predictive and proactive care paradigms.
In a parallel development in the healthcare technology space, Thyme Care, which specializes in value-based cancer care platforms, successfully secured $60 million in Series B financing, bringing their total funding to over $80 million. The funding round saw active participation from Town Hall Ventures and Foresite Capital, among other returning investors such as Andreessen Horowitz Bio + Health and Casdin Capital.
As part of its strategic expansion, Thyme Care plans to broaden its network of oncology partners and enhance its cancer care support services. Key healthcare figures David Whelan and Elizabeth Canis have joined Thyme’s board, bringing valuable executive experience from their previous roles at Elevance and UnitedHealthcare respectively. David Whelan highlighted the transformational focus of Thyme Care, noting its commitment to prioritizing patient care and spearheading the shift towards value-based healthcare frameworks.
Elsewhere in the healthcare tech funding landscape, Neuspera Medical, Inc. completed a $23 million Series D funding round, led by Vertex Ventures HC and Treo Ventures. With additional financial input from Windham Venture Partners and other strategic investors, Neuspera aims to progress its pioneering Neuspera Implantable Sacral Neuromodulation System through the rigorous FDA premarket approval process. This innovative device is designed to assist patients in managing symptoms of an overactive bladder, including urinary incontinence.
Gabriela Kaynor of Olympus Innovation Ventures expressed optimism about the investment in Neuspera, highlighting the critical market need for such innovative treatments, robust clinical trial feedback, and patient demand as key drivers for their commitment.
These funding rounds serve as significant endorsements for ongoing innovations in healthcare technology, with Huma, Thyme Care, and Neuspera exemplifying the dynamic advancements and strategic investments aiming to transform patient care and medical outcomes.
Moreover, industry stakeholders and professionals will have an opportunity to delve deeper into these innovations at the upcoming HIMSS AI in Healthcare Forum. Scheduled for September 5-6 in Boston, this event promises to be a critical platform for discussing future trends, challenges, and advancements in healthcare AI applications, potentially featuring insights from these leading companies.
#Digital #health #tech #company #Huma #scores #80M #digital #health #raises
